Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

PR Newswire
January 29, 2022 — 05:28 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: biotech China chinese European finance Finland GMO guangdong healthcare Hong Kong investment pharmaceutical Shanghai shenzhen Switzerland taiwan technology

Related News:

Cybellum Receives Frost & Sullivan’s Competitive Strategy Award for its Innovative Product Security Solutions

September 27, 2024 — 01:00

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Announcement of ICAIRE’s Classification as a UNESCO Category 2 Center at the Global AI Summit

September 11, 2024 — 02:34

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

Telin and Indosat Ooredoo Hutchison Partner to Develop the Indonesia Cable System Express 2 (ICE System 2)

August 28, 2024 — 20:46

LAZADA GROUP RELEASES ANNUAL ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) IMPACT REPORT FOR FINANCIAL YEAR 2024

August 27, 2024 — 11:00

Hyundai Motor Group Companies’ Ratings Upgraded by Global Top Rating Agencies

August 26, 2024 — 17:24

WSPN Appoints Ex-Visa President John Partridge as Board Director

August 22, 2024 — 11:22

Franchising and Licensing Asia (FLAsia) 2024